[go: up one dir, main page]

MX2009005849A - Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. - Google Patents

Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.

Info

Publication number
MX2009005849A
MX2009005849A MX2009005849A MX2009005849A MX2009005849A MX 2009005849 A MX2009005849 A MX 2009005849A MX 2009005849 A MX2009005849 A MX 2009005849A MX 2009005849 A MX2009005849 A MX 2009005849A MX 2009005849 A MX2009005849 A MX 2009005849A
Authority
MX
Mexico
Prior art keywords
compositions
methods
cancer
aeruginosa
present
Prior art date
Application number
MX2009005849A
Other languages
English (en)
Inventor
Ananda Chakrabarty
Gupta Tapas Das
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2009005849A publication Critical patent/MX2009005849A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden ADN rico en CpG a partir de Pseudomonas aeruginosa. Las composiciones opcionalmente comprenden una cupredoxina. La presente invención incluye ADNs de CpG específicos apartir de Pseudomonas aeruginosa, que son empledos para tratarcáncer y otras condiciones en pacientes. Estas composiciones están opcionalmente en un portador farmacéuticamente aceptable y también comprendenopcionalmente una cupredoxina. La presente invención además se refiere a métodos para expresar proteínas cerca de células de cáncer. Estos métodos pueden ser usados para expresarproteínas de diagnósticas cerca de células de cáncer en un paciente que sufre de cáncer u otras condiciones, y también pueden ser usados pára diagnosticar cáncer en un paciente. Este método usa el gen de azurina a partir de P. aeruginosa como un sistema de expresión para azurina o proteínas heterólogas en P. aeruginosa células hetrólogas.
MX2009005849A 2006-12-04 2007-12-04 Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas. MX2009005849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87247106P 2006-12-04 2006-12-04
PCT/US2007/086393 WO2008070672A2 (en) 2006-12-04 2007-12-04 Compositions and methods to treat cancer with cupredoxins and cpg rich dna

Publications (1)

Publication Number Publication Date
MX2009005849A true MX2009005849A (es) 2009-08-12

Family

ID=39493039

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005849A MX2009005849A (es) 2006-12-04 2007-12-04 Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.

Country Status (12)

Country Link
US (3) US8017749B2 (es)
EP (1) EP2089411A4 (es)
JP (2) JP2010511408A (es)
KR (1) KR20090095626A (es)
CN (1) CN101600728A (es)
AU (1) AU2007329375A1 (es)
BR (1) BRPI0718360A2 (es)
CA (1) CA2671492A1 (es)
MX (1) MX2009005849A (es)
NO (1) NO20092522L (es)
RU (1) RU2009125599A (es)
WO (2) WO2008070666A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2000061151A2 (en) 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US20030199466A1 (en) * 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
CN101948835A (zh) * 2002-10-29 2011-01-19 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
EP1797114A4 (en) * 2004-10-07 2009-07-15 Ananda Chakrabarty CUPREDOXIN-DERIVED TRANSPORT AGENTS AND METHODS OF USE
WO2008070666A2 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cpg rich dna and cupredoxins
RU2009133473A (ru) * 2007-02-08 2011-03-20 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Композиции и способы для предотвращения рака с помощью купредоксинов
PE20110998A1 (es) 2008-12-09 2012-02-10 Coley Pharm Group Inc Oligonucleotidos inmunoestimuladores
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
WO2014049604A2 (en) * 2012-09-05 2014-04-03 Amrita Therapeutics Limited A novel biomedical device for cancer therapy
MX2015007794A (es) * 2012-12-21 2015-09-04 Teva Pharma Suministro transmucosal de acetato de glatiramer mediante parches orales.
EP3115039B1 (de) * 2015-07-09 2021-12-15 beniag GmbH Verfahren zum herstellen einer fusionsmischung zur übertragung eines geladenen moleküls in und/oder durch eine lipidmembran
RU204475U1 (ru) * 2020-09-24 2021-05-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт медицины труда имени академика Н.Ф. Измерова" (ФГБНУ "НИИ МТ") Медицинский аппликатор для местного лечения кожных заболеваний
CN119367528A (zh) * 2024-10-25 2025-01-28 重庆医科大学附属第二医院 联合CpG-ODN佐剂的铜绿假单胞菌DNA疫苗的制备方法及应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6167490A (ja) * 1984-09-07 1986-04-07 Sagami Chem Res Center Ｐ▲ｌ▼プロモ−タ−を有する環状二重鎖ｄｎａ
US4817384A (en) 1986-08-13 1989-04-04 Toyota Jidosha Kabushiki Kaisha Double air-fuel ratio sensor system having improved exhaust emission characteristics
US5252317A (en) 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5567411A (en) 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5760191A (en) 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US5417959A (en) 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5520904A (en) 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
US5801228A (en) 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
DK0873341T3 (da) 1995-11-17 2004-01-19 Biotechnolog Forschung Gmbh Epothilonderivater, fremstilling og anvendelse
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5804161A (en) 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US6383500B1 (en) 1996-06-27 2002-05-07 Washington University Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications
WO1998022461A1 (de) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US7807182B2 (en) 1996-12-31 2010-10-05 Colorado State University Research Foundation Early detection of mycobacterial disease using peptides
DE59805110D1 (de) 1997-02-25 2002-09-12 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte epothilone
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
WO1999002224A1 (en) 1997-07-07 1999-01-21 Lewis Robert D Statistical analysis and feedback system for sports employing a projectile
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1001951B1 (de) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
FR2766185B1 (fr) 1997-07-18 2001-06-15 Rhone Poulenc Rorer Sa Medicaments contenant en tant que principe actif au moins un derive substitue de polyhydroxylalkylpyrazines, les nouveaux derives polyhydroxylalkylpyrazines et leur preparation
CA2299608A1 (en) 1997-08-09 1999-02-18 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
IT1297288B1 (it) 1997-10-31 1999-09-01 Denis Robert Gemmani Struttura di grigliato metallico dentellato particolarmente per il completamento di manufatti ed opere edili ad uso civile od industriale
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1058679B1 (en) 1998-02-25 2005-10-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
AU4775299A (en) 1998-06-22 2000-01-10 Nicolaou, Kyriacos Costa Desmethyl epothilones
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
ATE398175T1 (de) * 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US7556810B2 (en) * 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7301010B2 (en) * 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7381701B2 (en) * 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7338766B2 (en) * 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7618939B2 (en) * 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
KR20030081445A (ko) * 2001-02-15 2003-10-17 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 세포 사멸을 조절하는 세포독성인자
US7338776B2 (en) 2002-03-20 2008-03-04 Jcr Pharmaceuticals Co., Ltd. Production of UGPPase
KR100456681B1 (ko) * 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CN1506375A (zh) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
CN100486987C (zh) 2003-03-05 2009-05-13 长春华普生物技术有限公司 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸
US8158574B2 (en) * 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
US20090208476A1 (en) * 2006-05-19 2009-08-20 Tapas Das Gupta Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US9968685B2 (en) * 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
EP1797114A4 (en) * 2004-10-07 2009-07-15 Ananda Chakrabarty CUPREDOXIN-DERIVED TRANSPORT AGENTS AND METHODS OF USE
US10675326B2 (en) * 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US7807183B2 (en) * 2005-07-19 2010-10-05 The Board Of Trustees Of The University Of Illinois Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof
KR20080024124A (ko) * 2005-05-20 2008-03-17 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬 ｃ로 ｈｉｖ 감염을 치료하기 위한조성물과 방법
CA2615560A1 (en) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions and methods to control angiogenesis with cupredoxins
JP4582004B2 (ja) * 2006-01-13 2010-11-17 セイコーエプソン株式会社 発光装置および電子機器
US20140287990A1 (en) * 2006-05-19 2014-09-25 The Board Of Trustees Of The University Of Illinois Compositions and methods to concurrently treat and/or prevent multiple diseases with cupredoxins
US10266868B2 (en) * 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
KR100801002B1 (ko) * 2006-06-05 2008-02-11 삼성전자주식회사 무선 네트워크 상에서 멀티미디어 데이터를 전송/재생하는방법, 및 그 방법을 이용한 무선 기기
CN101600447A (zh) * 2006-09-11 2009-12-09 伊利诺斯大学理事会 铜氧还蛋白衍生肽类的修饰物及其使用方法
AU2007296429A1 (en) * 2006-09-14 2008-03-20 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US8685720B2 (en) * 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
WO2008070666A2 (en) * 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cpg rich dna and cupredoxins
RU2009133473A (ru) * 2007-02-08 2011-03-20 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Композиции и способы для предотвращения рака с помощью купредоксинов
WO2009078977A2 (en) * 2007-12-14 2009-06-25 Cdg Therapeutics Inc Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins
JP5873499B2 (ja) * 2010-10-01 2016-03-01 アムリタ セラピューティクス リミテッドＡｍｒｉｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 抗がん剤
PT2574597E (pt) * 2011-09-30 2016-02-08 Elaflex Hiby Tanktechnik Gmbh & Co Válvula de distribuição
WO2017012661A1 (en) * 2015-07-22 2017-01-26 Curetis Gmbh Genetic testing for predicting resistance of pseudomonas species against antimicrobial agents
KR102024186B1 (ko) * 2017-05-04 2019-09-23 주식회사 젠센 톨-유사 수용체(tlr) 억제를 위한 펩타이드 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
JP2014158486A (ja) 2014-09-04
WO2008070672A3 (en) 2009-04-16
WO2008070672A2 (en) 2008-06-12
CA2671492A1 (en) 2008-06-12
BRPI0718360A2 (pt) 2013-11-12
CN101600728A (zh) 2009-12-09
US8017749B2 (en) 2011-09-13
WO2008070666A2 (en) 2008-06-12
WO2008070666A3 (en) 2009-04-09
US9969781B2 (en) 2018-05-15
US11046733B2 (en) 2021-06-29
US20120014877A1 (en) 2012-01-19
NO20092522L (no) 2009-09-04
US20200172581A1 (en) 2020-06-04
JP2010511408A (ja) 2010-04-15
EP2089411A2 (en) 2009-08-19
AU2007329375A2 (en) 2009-08-13
US20090226405A1 (en) 2009-09-10
EP2089411A4 (en) 2010-01-27
AU2007329375A1 (en) 2008-06-12
KR20090095626A (ko) 2009-09-09
RU2009125599A (ru) 2011-01-20

Similar Documents

Publication Publication Date Title
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
MX2007001638A (es) Proteinas de fusion del dominio de unión.
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
MA33717B1 (fr) Immunoconjugués ciblés
WO2008060510A3 (en) Zinc finger nuclease for targeting the human glucocorticoid receptor locus
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP2308885A3 (en) Novel compounds and methods for therapy
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
GB2471588A (en) Therapeutic peptidomimetic macrocycles
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
IN2015DN00255A (es)
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
PH12013500826A1 (en) Means and methods for treating dlbcl
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
IN2012DN02645A (es)
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
GB0418388D0 (en) Cell therapy
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders

Legal Events

Date Code Title Description
FG Grant or registration